To test whether neutralization of CXCL10/CXCR3 signaling also decreases inflammatory macrophages in vivo, we treated KC mice with a CXCR3 neutralization antibody (CXCR3 NAB) or an isotype control IgG antibody over a period of 9 weeks (Figure 3—figure supplement 1E). The gene discussed is CXCR3; the disease is keratoconus.